1 F), and a decreasing trend in TC and HDL-C (Fig. 1 G, I).
← all excerpts
Naringenin cationic lipid-modified nanoparticles mitigate MASLD progression by modulating lipid homeostasis and gut microbiota.
2
—
—
The sentences
Conversely, NAR and NP-NAR interventions significantly reduced NEFA and VLDL levels ( p < 0.001), with an increasing trend in Apo-B levels (Fig. 1 J-L), and NP-NAR acted significantly better than NAR in lowering hepatic NEFA and VLDL ( p < 0.001).